Oruka Therapeutics, Inc.
ORKA Nasdaq
SEC CIK 907654
Follow Oruka Therapeutics
Weekly email: filings, results
Net income
−$50M
−65% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$44.3M
−105.2% vs same quarter last year
Operating income
−$62.1M
−82.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$105.4M |
| FY24 | - | −$83.7M |
| FY23 | $0 | −$5.3M |
| FY22 | $0 | −$9.9M |
| FY21 | $0 | −$19.3M |
| FY20 | $0 | −$9.7M |
| FY19 | $0 | −$5.5M |
| FY18 | $0 | −$7.9M |
| FY17 | $0 | −$18.5M |
| FY16 | $0 | −$16.4M |
| FY15 | $0 | −$11.4M |
| FY14 | $0 | −$9.7M |
| FY13 | - | −$6.9M |
| FY12 | - | −$4.3M |
| FY11 | - | −$5.4M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$88.4M |
| FY24 | - |
| FY23 | −$5M |
| FY22 | −$10.9M |
| FY21 | −$18.8M |
| FY20 | −$7.7M |
| FY19 | −$4.8M |
| FY18 | −$8.2M |
| FY17 | −$17.5M |
| FY16 | −$15M |
| FY15 | −$10.5M |
| FY14 | −$9.4M |
| FY13 | −$5.3M |
| FY12 | - |
| FY11 | −$7M |